Exhibit 99.5

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS OF

ENDOLOGIX, INC. AS OF JUNE 30, 2015 AND FOR THE YEAR ENDED DECEMBER 31, 2014

AND FOR THE SIX MONTHS ENDED JUNE 30, 2015

On October 26, 2015, Endologix, Inc., (“Endologix”) entered into an agreement and plan of merger with TriVascular Technologies, Inc. (“TriVascular”). Under the terms of the agreement, Endologix agreed to acquire all of TriVascular’s outstanding capital stock through a merger of a direct wholly-owned subsidiary of Endologix with TriVascular (the “Merger”). The Merger will provide the newly combined company, following the closing of the transaction, with a strategic competitive advantage in R&D and product development expansion, retaining existing customers and expanding its customer base. The aggregate consideration payable to the stockholders of TriVascular in the Merger consists of approximately $187 million of Endologix common stock and up to $24 million in cash. Contemporaneous to the Merger, Endologix intends to issue $150 million in     % Senior Convertible Notes.

The following unaudited pro forma condensed combined statements of operations for the six month period ended June 30, 2015, and the year ended December 31, 2014, are presented as if the Merger and the contemporaneous financing transaction had been completed on January 1, 2014. The unaudited pro forma condensed combined balance sheet as of June 30, 2015, is presented as if the Merger and the contemporaneous financing transaction had been completed on June 30, 2015. The unaudited pro forma condensed combined financial statements presented below are derived from the historical consolidated financial statements of Endologix and the historical consolidated financial statements of TriVascular. The historical consolidated financial statements of Endologix and TriVascular are presented in accordance with accounting principles generally accepted in the United State of America (“US GAAP”).

As described in the accompanying notes, the unaudited pro forma condensed combined financial statements have been prepared using the acquisition method of accounting under US GAAP and the regulations of the SEC. US GAAP requires that one of the companies in the Merger be designated as the accounting acquirer for the purposes of applying the acquisition method of accounting under ASC 805, Business Combinations. Endologix is the accounting acquirer.

The historical financial statements have been adjusted in the unaudited pro forma condensed combined financial statements to give effect to the pro forma events that are (i) directly attributable to the Merger; (ii) factually supportable; and (iii) with respect to the unaudited pro forma condensed combined statements of operations, expected to have a continuing impact on the combined results. The unaudited pro forma condensed combined statements of operations exclude non-recurring items, that are directly related to the Merger, including, but not limited to: (i) Merger related legal and advisory fees; and (ii) the impact of a fair value inventory step-up on the cost of goods sold. Additionally, certain pro forma adjustments have been made to the historical consolidated financial statements of TriVascular in order to conform their financial statement presentation policies to those applied by Endologix.

Because the acquisition method of accounting is dependent upon certain valuations and other studies that must be prepared as of the completion date of the Merger and because there are limitations on the type of information that can be exchanged between Endologix and TriVascular at this time, there currently is not sufficient information for a definitive measurement; therefore, the unaudited pro forma condensed combined financial statements are preliminary. Until the Merger is complete, Endologix will not have complete access to all relevant information. In determining the preliminary estimate of fair values of TriVascular’s assets that will be acquired and liabilities that will be assumed, Endologix used publically available benchmarking information, as well as a variety of other assumptions, including market participant assumptions. Differences between these preliminary estimates and the final acquisition accounting will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial statements and the combined future results of operations and financial position.

The unaudited pro forma condensed combined financial statements do not give effect to the potential impact of any anticipated synergies, operating efficiencies or cost savings that may result from the Merger or any integration costs. The unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and do not purport to represent what the actual consolidated results of operations or the consolidated financial position of the newly combined company would have been had the Merger occurred on the dates assumed, nor are they necessarily indicative of future consolidated results of operations or consolidated financial position.

Unaudited Pro Forma Condensed Combined Balance Sheet

(dollars in thousands)

2

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Six Months Ended June 30, 2015

(dollars and weighted average shares outstanding in thousands, except per share amounts)

3

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Year Ended December 31, 2014

(dollars and weighted average shares outstanding in thousands, except per share amounts)

4

The unaudited pro forma condensed combined financial statements have been prepared in accordance with Article 11 of Regulation S-X. The historical financial information has been adjusted to give effect to transactions that are (i) directly attributable to the Merger, (ii) factually supportable and (iii) with respect to the unaudited pro forma condensed combined statement of operations, expected to have a continuing impact on the operating results of the combined company. The historical consolidated financial statements of Endologix and TriVascular are presented in accordance with U.S. GAAP.

The unaudited pro forma condensed combined balance sheet as of June 30, 2015 was prepared using the historical unaudited consolidated balance sheets of Endologix and TriVascular as of June 30, 2015, and presents the combined financial position of Endologix and TriVascular as if the Merger occurred on June 30, 2015. The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2015 and the year ended December 31, 2014 assume that the Merger was consummated on January 1, 2014.

Endologix’s historical financial information for the year ended December 31, 2014 and as of and for the six month period ended June 30, 2015 is derived from Endologix’s Form 10-K and Form 10-Q filed with the SEC on March 2, 2015 and August 5, 2015, respectively. The historical financial information for TriVascular for the year ended December 31, 2014 and as of and for the six month period ended June 30, 2015 is derived from TriVascular Technologies’ Form 10-K and Form 10-Q filed with SEC on March 9, 2015 and August 5, 2015, respectively.

The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2015 and the year ended December 31, 2014, have not been adjusted for the following estimated amounts that are expected to have a one-time impact on the pro forma combined loss from continuing operations in the twelve months following the Merger (in thousands):

The tax impact of the amounts in the table above are disclosed in footnote 5(e) below.

The unaudited pro forma condensed combined financial statements have been prepared using the acquisition method of accounting in accordance with the business combination accounting guidance as provided in Accounting Standards Codification 805, Business Combinations, with Endologix treated as the accounting acquirer.

The unaudited pro forma condensed combined financial information should be read in conjunction with:

5

The accounting policies used in the preparation of these unaudited pro forma condensed combined financial information are those set out in Endologix’s audited financial statements as of December 31, 2014. Management has determined that no significant adjustments are necessary to conform TriVascular’s financial statements to the accounting policies used by Endologix in the preparation of the unaudited pro forma condensed combined financial information. Certain reclassifications have been reflected in the pro forma adjustments to conform TriVascular’s presentation to Endologix’s in the pro forma balance sheet and statement of operations. Specifically, reclassifications have been made to the statement of operations between TriVascular’s presentation of operating expenses, including Research and Development and Endologix’s Clinical and Regulatory Affairs, as well as TriVascular’s presentation of Sales, General, and Administrative expenses and Endologix’s General and Administrative and Marketing and Sales expenses. These reclassifications were prepared to conform to Endologix’s presentation of operating expenses in the statement of operations. These reclassifications were prepared using the account descriptions in TriVascular’s trial balance. These reclassifications have no effect on previously reported total assets, total liabilities and shareholders’ equity, or income from continuing operations of Endologix or TriVascular. The pro forma financial information may not reflect all reclassifications necessary to conform TriVascular’s presentation to that of Endologix, due to limitations on the availability of information as of the date of this prospectus. Accounting policy differences and additional reclassification adjustments may be identified as more information becomes available.

The fair value of the Merger Consideration expected to be transferred on the closing date includes the value of the estimated cash consideration and the estimated fair value of the equity to be transferred as per the Merger Agreement. The aggregate consideration payable to the stockholders of TriVascular per the Merger Agreement consists of 19.999% of Endologix issued and outstanding Common Stock as of the Effective Time, estimated to be approximately $187 million equity consideration and up to $24 million in cash consideration. For the purposes of estimating the Merger Consideration, the Company estimated the cash consideration that will be provided to common shares estimated to be issued for existing stock options, RSUs, convertible notes, and common stock warrants as of October 23, 2015 in items (2) through (7) as disclosed in the below table. The calculation of Merger Consideration is as follows (in thousands):

6

The following table shows the effect of a change in Endologix’s stock price and the resulting impact on the estimated merger consideration and estimated goodwill (dollars in thousands, except stock price):

Preliminary Purchase Price Allocation

Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of TriVascular are recorded at the acquisition date fair values and added to those of Endologix. The pro forma adjustments are preliminary and based on estimates of the fair value and useful lives of the assets acquired and liabilities assumed and have been prepared to illustrate the estimated effect of the Merger. The final determination of the purchase price allocation upon the closing of the Merger will be based on TriVascular’s net assets acquired as of that date and will depend on a number of factors, which cannot be predicted with any certainty at this time. The purchase price allocation may change materially based on the receipt of more detailed information. Therefore, the actual allocations will differ from the pro forma adjustments presented. The allocation is dependent upon certain valuation and other studies that have not yet been completed. Accordingly, the pro forma purchase price allocation is subject to further adjustment as additional information becomes available and as additional analyses and final valuations are completed. There can be no assurances that these additional analyses and final valuations will not result in significant changes to the estimates of fair value set forth below.

7

The following table sets forth a preliminary allocation of the estimated merger consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of TriVascular based on TriVascular’s June 30, 2015 balance sheet, with the excess recorded as goodwill (in thousands):

Preliminary identifiable intangible assets in the pro forma financial information consist of anticipated intangibles derived from developed technology, in-process technology, customer related assets, the TriVascular trade name, and covenants not to compete. The amortization related to the amortizable identifiable intangible assets acquired is reflected as a pro forma adjustment in the unaudited pro forma condensed combined statements of operations, as further described in Note 5(a). The identifiable intangible assets and related amortization are preliminary and are based on management’s estimates after consideration of similar transactions. As discussed above, the amount that will ultimately be allocated to identifiable intangible assets and liabilities, and the related amount of amortization, may differ materially from this preliminary allocation. In addition, the periods the amortization impacts will ultimately be based upon the periods in which the associated economic benefits or detriments are expected to be derived, or where appropriate, based on the use of a straight-line method. Therefore, the amount of amortization following the Transactions may differ significantly between periods based upon the final value assigned, and amortization methodology used for each identifiable intangible asset.

Deferred tax assets and liabilities have not been established for the adjustments above as it is anticipated that the adjustments will be in entities with a deferred tax valuation allowance.

Goodwill represents the excess of the preliminary estimated merger consideration over the fair value of the underlying net assets acquired. Goodwill is not amortized but instead is reviewed for impairment at least annually, absent any indicators of impairment. Goodwill is attributable to planned growth and synergies expected to be achieved from the combined operations of Endologix and TriVascular. Goodwill recognized in the Merger is not expected to be deductible for tax purposes.

8

TriVascular had no accrued interest as of June 30, 2015. Refer to Note 5(c) for additional details regarding the Senior Convertible Notes.

9

The allocation of proceeds to the conversion feature results in a $51.9 million discount on the Senior Convertible Notes which reduces their carrying value from $150 million to $98.2 million. The discount is amortized over the term of the Senior Convertible Notes such that total effective interest expense approximates 13.6%. The allocation was performed by first determining the fair value of the Liability Component. That amount was then deducted from the initial proceeds of the Senior Convertible Notes as a whole to arrive at a residual amount, which was allocated to the Equity Component and the carrying value of the Senior Convertible Notes based on their relative fair values.

For purposes of the unaudited pro forma condensed combined June 30, 2015 balance sheet only, Endologix has estimated that the associated financing fees will total $4.3 million. Of this amount, $3.8 million are estimated to be capitalized and $0.5 million are estimated to be allocable to the Equity Component. Fees allocable to the Equity Component are regarded as equity issuance costs and accounted for as a reduction to additional paid in capital.

10

The adjustment for the amortization of the identifiable intangible assets is as follows:

The table below indicates the estimated fair value of each of the identifiable intangible assets and estimated useful life of each (in thousands):

In-Process Technology will be accounted for as an indefinite-lived intangible asset until the underlying projects are completed or abandoned. Solely for the purposes of estimating the fair values of the intangible assets in this unaudited pro forma condensed combined financial information, benchmarking information, publicly available information as well as a variety of other assumptions including market participant assumptions were used.

11

Each 1/8% increase in the stated interest rate on the Senior Convertible Notes would result in a $0.1 million increase in interest expense for the six months ended June 30, 2015. The following table shows the effect of a change in estimated all-in effective interest rate and the resulting discount on the Senior Convertible Notes at inception and interest expense for the six months ended June 30, 2015 (dollars in thousands):

Each 1/8% increase in the stated interest rate on the Senior Convertible Notes would result in a $0.2 million increase in interest expense for the twelve months ended December 31, 2014. The following table shows the effect of a change in estimated all-in effective interest rate and the resulting discount on the Senior Convertible Notes at inception and interest expense for the twelve months ended December 31, 2014 (dollars in thousands):

12

13